#Pharma #Bourse After oral care, GSK's attention now shifts to #OTC products | Business Standard http://t.co/y248XFDCZO
July 04, 2013
/http%3A%2F%2Fbsmedia.business-standard.com%2F_media%2Fbs%2Fimg%2Farticle%2F2013-02%2F05%2Ffull%2F1360051285-3312.jpg)
After oral care, GSK's attention now shifts to OTC products
The consumer arm of British pharma major GlaxoSmithKline (GSK) is extending its popular antacid Eno, used to cure acidity and other gastric issues, into tablets and liquids in a bid to take on rivals such as Digene from Abbott and Gelusil from Pfizer. The 75-year-old Eno is currently available only in powder format.